logo

Hot News show next Hot News

3SBio’s Q3 Hurt by Lehman Bankruptcy
By: China Bio Today   Monday, November 03, 2008 7:05 PM
Sectors: Medical
Symbols: SSRX
enter symbol
enter search string

Join Blog Network
Alerts by Email
Research Articles
Stock Ranking Changes
submit article
3SBio Inc. (NSDQ: SSRX) announced a $2.7 million writedown as a consequence of the US financial crisis. The company invested in $3 million of Floating Rate Notes due January 21, 2009 that are subject to the credit of Lehman Brothers. As a consequence of the Lehman Brothers bankruptcy, the notes have been given a value of $300,000. The notes were credit default swaps issued by UBS AG, and they are linked to credit of Lehman Brothers Holdings Inc.

3SBio said that the rest of its 58.7 million RMB ($8.6 million) bond portfolio is in good shape. It also noted a $99.5 million cash balance at the end of the third quarter.

3SBio made the announcement as part of its preliminary Q3 unaudited results. The company said its Q3 revenues climbed 22% to 68.2 million RMB ($10.0 million). However, because of the charge, net income dropped to 1.9 million RMB ($0.3 million), or $0.01 per ADS. In last year’s Q3, 3SBio reported revenues of $7.5 million and net income of $3.2 million. 3SBio cautioned that this year’s numbers, being preliminary, are subject to revision.

The company reiterated its full-year 2008 revenue guidance of $34 to $35 million.

3SBio slipped 24 cents lower to $6 in today’s trading. It has traded in a range between $5.16 and $20 over the past 12 months.




Subscribe to Email Alerts rss feed or RSS feeds rss feed for articles from more than 300 contributors and press releases, SEC filings and full text news from thousands of sources.
(0)
No Comments

Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia